Home>Topics>Stocks>Intrepid Potash

Intrepid Potash IPI

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Fertilizer estimates lowered at Cowen, Potash downgraded

      Headlines

      Tue, 9 Sep 2014

      a reduced fertilizer forecast and downgrades Potash (NYSE: POT ) to Underperform from Market Perform as well as Mosaic (NYSE: MOS ) to Sector Perform from Outperform; POT -1% premarket. Also: CF , AGU , IPI , RNF . Post your comment!

    2. Infiniti and Roche ink supply agreements

      Headlines

      Wed, 3 Sep 2014

      planned clinical studies to evaluate the combination of Gazyva and IPI -145 (duvelisib) as a treatment for patients with blood cancers ..... consummate a material transfer agreement whereby Infiniti will supply IPI -145 to Roche to use in its preclinical and translational research

    3. Infinity Pharma and AbbVie ink development deal

      Headlines

      Wed, 3 Sep 2014

      NYSE: ABBV ) and Infinity Pharmaceuticals (NASDAQ: INFI ) enter into a global collaboration to develop and commercialize IPI -145 ( duvelisib ), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment

    4. Dropping Coverage of Intrepid Potash

      Commentary

      Tue, 12 Aug 2014

      We are dropping analyst coverage of Intrepid Potash . We provide broad coverage of more than 1,500 companies across more than 90 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    5. Infinity Pharma buys an option on future IPI -145 royalties

      Headlines

      Mon, 4 Aug 2014

      Millennium Pharmaceuticals for sales of IPI -145, Infinity's oral PI3K inhibitor ..... to Millennium future royalties related to IPI -145 in oncology. Infinity may exercise ..... that gain regulatory approval, including IPI -145. The remaining payments include up

    6. New Morningstar Analyst Report for Pharmacyclics Inc

      Stock Reports

      Fri, 1 Aug 2014

      cancers, several competitors are following close behind. Gilead's idelalisib has recently been approved and Infinity's IPI -145, and AbbVie/Roche's ABT-199 are in Phase III studies. Earlier-stage Ono Pharmaceutical's ONO-4059 and Celgene's

    7. New Morningstar Analyst Report for Intrepid Potash Inc

      Stock Reports

      Thu, 31 Jul 2014

      but we'll be keeping an eye out to make sure management doesn't make a habit out of raising project cost estimates. Intrepid Potash is a U.S. producer of potash (1,000,000 tons of capacity) and langbeinite (240,000 tons of capacity) operating

    8. With a Big Capital Investment Cycle Nearly Complete, Intrepid Should Enjoy Lower Costs Ahead

      Commentary

      Thu, 31 Jul 2014

      We’re raising our fair value estimate for Intrepid Potash to $16 per share from $15 per share following the release of second-quarter results. Our fair value estimate boost reflects

    9. Intrepid's New Solar Solution Mine Will Bring Down Companywide Costs per Ton

      Commentary

      Thu, 1 May 2014

      We're holding steady on our $15-per-share fair value estimate for Intrepid Potash following the release of the company's first-quarter results. Our no-moat rating remains intact. Despite a big jump in

    10. Potash Cartel Is on the Mend; We Expect to Boost Fair Value Estimates for Potash Producers

      Commentary

      Thu, 6 Mar 2014

      heavily on fertilizer mix at the individual company level. For example, the effect will be much greater on pure-play Intrepid Potash than diversified Agrium. We also expect to re-examine other parts of our valuations for potash producers when implementing

    « Prev12345Next »
    Content Partners